| abstract |
The present invention provides a selective phosphoinositide 3-kinase inhibitor of formula (A), or a pharmaceutically acceptable salt thereof. These compounds are useful for the treatment of symptoms mediated by one or more P13K isoforms, such as PI3K delta (PI3Kδ). The present invention further provides a method of inhibiting phosphoinositide 3-kinase inhibitors using these compounds for the treatment of disorders associated with phosphatidylinositol 3-kinase activity. |